D
Lexicon Pharmaceuticals, Inc. LXRX
$0.3677 $0.03179.44%
Recommendation
Sell
Prev Close
$0.336
Volume
13,170,599
Avg Vol (90D)
5,556,315
Market Cap
$121.46M
Dividend & Yield
--
52-Week Range
$0.2836 - $2.83
P/E (TTM)
--
EPS (TTM)
-$0.7515
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
3/6/2025 - Zacks Investment Research
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ...
3/6/2025 - GuruFocus
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
3/6/2025 - Globe Newswire
Leerink Partnrs Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold
3/6/2025 - Ticker Report
Leerink Partners Reiterates Market Perform Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
3/5/2025 - MarketBeat
Lexicon Pharmaceuticals Q4 2024 Earnings Preview
3/5/2025 - SeekingAlpha.com: All News
Leerink Partners Reiterates Market Perform Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
3/4/2025 - Ticker Report
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March ...
3/4/2025 - GuruFocus
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
3/4/2025 - Globe Newswire
Private equity firms who have a significant stake must be disappointed along with institutions after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap dropped by US$148m
3/4/2025 - Simply Wall St
Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Buy" Rating from HC Wainwright
3/3/2025 - MarketBeat
Needham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
3/3/2025 - MarketBeat
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating ...
3/3/2025 - GuruFocus
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
3/3/2025 - Globe Newswire
Lexicon Pharmaceuticals (LXRX) Projected to Post Quarterly Earnings on Monday
3/3/2025 - MarketBeat
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating ...
3/2/2025 - GuruFocus
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating ...
3/2/2025 - GuruFocus
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
3/2/2025 - Globe Newswire
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
2/18/2025 - Globe Newswire
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Exact Sciences (EXAS) and Amgen (AMGN)
1/30/2025 - TipRanks Financial Blog
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given Hold Rating at Needham & Company LLC
1/30/2025 - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Buy" Rating from HC Wainwright
1/30/2025 - MarketBeat
Promising Outlook for Lexicon Pharmaceuticals' LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
1/30/2025 - TipRanks Financial Blog
Lexicon Pharmaceuticals jumps amid takeover speculation
1/29/2025 - SeekingAlpha.com: All News
Lexicon Pharmaceuticals jumps amid takeover speculation
1/29/2025 - Seeking Alpha - Healthcare
Income Statement
Total Revenue (TTM)
$5.23M
EBITDA (TTM)
-$210.56M
EBIT (TTM)
-$211.12M
Net Income (TTM)
-$216.39M
Balance Sheet
Total Assets (Q)
$321.12M
Total Debt (Q)
$105.87M
Total Liabilities (Q)
$142.61M
Book Value Per Share (Q)
$0.4938
Cash Flow
Cash from Operations (TTM)
-$207.84M
Cash from Investing (TTM)
-$17.18M
Cash from Financing (TTM)
$238.45M
Net Change in Cash (TTM)
$13.44M
Filings
Filing Date
Wednesday, November 13, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
2.21
7-Day Total Return
-43.90%
30-Day Total Return
-56.23%
60-Day Total Return
-43.43%
90-Day Total Return
-80.23%
Year to Date Total Return
-52.68%
1-Year Total Return
-83.21%
2-Year Total Return
-85.86%
3-Year Total Return
-82.66%
5-Year Total Return
-84.42%
52-week Low
Mar 03, 2025 - $0.2836
52-week High
Mar 12, 2024 - $2.83
Valuation
Market Cap
$121.46M - Micro Cap
Enterprise Value
-$31.03M
Price/Sales (TTM)
23.33
Price/Book (Q)
0.68
Dividends and Shares
Shares Outstanding
361.49M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lexpharma.com
Phone Number
281 863 3000
Address
2445 Technology Forest Boulevard
The Woodlands, TX 77381
Country
United States
Year Founded
1995
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug... more
NASDAQ 03/06/2025 4:00PM Eastern Quotes delayed
Weiss Ratings